China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Sees Significant Increase in Short Interest

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was the recipient of a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 3,408,880 shares, a growth of 1,863.4% from the December 31st total of 173,618 shares. Currently, 3.1% of the company’s shares are short sold. Based on an average daily volume of 41,428,043 shares, the days-to-cover ratio is presently 0.1 days. Based on an average daily volume of 41,428,043 shares, the days-to-cover ratio is presently 0.1 days. Currently, 3.1% of the company’s shares are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in China SXT Pharmaceuticals stock. Citadel Advisors LLC acquired a new position in shares of China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 48,759 shares of the company’s stock, valued at approximately $78,000. 5.02% of the stock is currently owned by hedge funds and other institutional investors.

China SXT Pharmaceuticals Trading Up 24.0%

Shares of NASDAQ SXTC traded up $0.02 during trading hours on Tuesday, hitting $0.10. The company had a trading volume of 146,248,432 shares, compared to its average volume of 24,376,332. China SXT Pharmaceuticals has a 1-year low of $0.08 and a 1-year high of $7.84. The firm’s 50 day moving average is $1.13 and its 200-day moving average is $1.40.

China SXT Pharmaceuticals (NASDAQ:SXTC) last posted its quarterly earnings results on Wednesday, December 31st. The company reported ($0.03) earnings per share (EPS) for the quarter. The business had revenue of $0.31 million for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of China SXT Pharmaceuticals in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, China SXT Pharmaceuticals currently has an average rating of “Sell”.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.